Review

Study progress of berberine for treating cardiovascular disease

Le-Min Xia*, Mei-Hong Luo

Department of Hematology, Baoshan Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai 201900, China

Received 21 April 2015
Available online 12 January 2016

Abstract

Berberine (BBR) is a natural alkaloid isolated from the Coptis chinensis. While this plant has been used in Chinese medicine for more than 2500 years, interest in its effects in treating cardiovascular disease has been growing in the last decade. Recent researches showed that BBR had the effect of anti-heart failure, anti-hypertension, anti-hyperlipidemia, anti-insulin resistance, anti-arrhythmias, and anti-platelet aggregation.

Berberine chemical characteristics and pharmacokinetics

BBR is a plant quaternary ammonium salt from the group of isoquinoline alkaloids (2, 3-methylenedioxy-9, 10-dimethoxyprotoberberine chloride; \( C_{20}H_{18}NO_{4} \)) with a molar mass of 336.36122 g/mol (Fig. 1). BBR is yellow in color, which is why in earlier times Berberis species were used to dye wool, leather, and wood. As a natural dye, berberine has a color index of 75160.2

Berberine has low bioavailability and shows poor absorption through the gut wall (<5%) and bowel P-glycoprotein appears to contribute to its poor absorption, actively expelling the alkaloid from the lumen mucosal cells.3

In a rat noncompartmental model, 4 unbound berberine is transported to bile through active transport

http://dx.doi.org/10.1016/j.cdtm.2015.11.006
2095-882X/© 2016 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
and it is metabolized by a p450 enzyme system in the liver, with phase I demethylation and phase II glucuronidation. Berberine has four main metabolites identified in rats: berberrubine, thalifendine, demethyleneberberine and jatrorrhizine (Fig. 1), all of which have glucuronide conjugates. Intestinal bacterial flora takes a role in enterohepatic circulation of berberine and its conjugated metabolites. On the other hand, a very small amount of unchanged berberine is eliminated in urine. Berberine may inhibit CYP2E1-like and CYP1A2, which is not related to a significant increase in the pharmacological interaction since most available drugs are not metabolized by these enzymatic systems.

Standard doses of berberine are generally well tolerated and eventual adverse events are rare and mild. On the contrary, high doses have been associated with arterial hypotension, dyspnea, flu-like symptoms, gastrointestinal discomfort, constipation, and cardiac damage. The most studied side effects are those in the gastrointestinal system. Berberine and derivatives can also produce gastric lesions.

The safety issue of berberine mostly involves the risk of some pharmacological interaction. In fact, berberine displaces bilirubin from albumin about 10-fold better than phenylbutazone, thus any herb containing large amounts of berberine should be avoided in jaundiced infants and pregnant woman. Berberine displaces warfarin, thiopental, and tolbutamide from their protein-binding sites, increasing their plasma levels (Fig. 2). Recent studies suggested that the mechanism of BBR for improving cardiac function may be related to increasing the concentration of calcium in cardiac muscle cells. The augmented cardiac contractile force is induced by progressively increasing the concentration of cyclic adenosine monophosphate (cAMP) in cardiac muscle cells by increasing an inward current carried by calcium ions in the intracellular of cardiac muscle mediated through alteration of cAMP. BBR increases high energy phosphate in heart failure and prevented ventricular fibrillation due to its effects on potassium channels, increased intracellular calcium, and suppressed the delay of depolarization partly due to sodium influx. On the other hand, BBR has a sympathetic activity-modulated effect on myocardium. In rats with experimentally induced cardiac hypertrophy by suprarenal aortic constriction, BBR decreased plasma noradrenaline and adrenaline levels and adrenaline in ventricular tissue, improved cardiac contractility with a shortened time to reach the maximum rate from the beginning of contraction and reduced the size of the left ventricular myocardium. In a dog ischemic heart failure model, intravenous berberine administration increased cardiac output, decreased left ventricular end-diastolic pressure and systemic vascular resistance. This activity was also confirmed in other animal models. Examination of hemodynamic parameters in humans reveals similar results with an increased cardiac index, increased left ventricular ejection fraction, decreased systemic and pulmonary vascular resistance and left ventricular end-diastolic pressures. In a clinical trial carried out on chronic heart failure patients, BBR decreased the frequency and complexity of ventricular premature complexes and increased the left ventricular ejection fraction.

**Effects of berberine on heart failure**

Fig. 2. (A) Berberrubine, C_{19}H_{16}ClNO_{4}; (B) Thalifendine, C_{19}H_{16}NO_{4}; (C) Demethyleneberberine, C_{19}H_{16}NO_{4}; (D) Jatrorrhizine C_{20}H_{20}ClNO_{4}.
BBR has been recognized as being capable of decreasing cardiovascular through reducing oxidative stress, low-density lipoprotein (LDL), triglycerides, and insulin resistance and improving the mood. A multicenter randomized trial showed BBR reduced LDL-c levels as well as total cholesterol/HDL-c and ApoB/ ApoA1 ratios, while increasing Apo A1, all of which are improvements in cardiovascular risk indicators.

**Effect of berberine on regulating blood pressure**

Systolic and diastolic blood pressures are correlated with cardiovascular events. A consistent theme in the literature has confirmed that there is a close correlation between blood pressure and atherosclerosis. Nitric oxide released from endothelium might primarily account for the BBR-induced endothelium-dependent relaxation, while activation of 4-aminopyridine and Ba2+-sensitive K+ channels, inhibition of intracellular Ca2+ release from caffeine-sensitive pools, or a direct relaxant effect are likely responsible for the BBR-induced endothelium-dependent relaxation. Mechanisms related to either Ca2+ influx or protein kinase C activation may not be involved. Both vasorelaxant and anti-proliferative effects may contribute to a long-term benefit of BBR in the vascular system.

**Effects of berberine on regulating blood lipids**

In lipid metabolism, the lipid-lowering effect of BBR appears to be mainly due to the stabilization of the hepatic LDL-C receptors (LDLR) by an extracellular signal regulated kinase (ERK)-dependent pathway and also by increasing transcriptional activity of the LDLR promoter by a c-Jun N terminal kinase (JNK) pathway. In addition, in 3T3-L1 cells leptin, transcription factors like sterol regulatory element binding protein-1c (SREBP-1c) and CCAAT enhancer-binding protein-α (C/EBP-α), peroxisome-proliferator activated receptor-γ (PPAR-γ), fatty acid synthase, acetyl-coenzyme A (acetyl-CoA) carboxylase, acyl-CoA synthase, and lipoprotein lipase are reduced by berberine treatment. Moreover, in addition to LDLR upregulation, berberine activates 5’ adenosine monophosphate (AMP) kinase (AMPK), while blocking the mitogen-activated protein kinase (MAPK)/ERK pathway, resulting in inhibition of lipid synthesis: its action on AMPK is eliminated by MEK inhibitors, suggesting a link between these two pathways. Other research showed BBR could counteract hyperlipidemia partially via upregulating LDLR and apoE mRNA levels and suppressing HMGR gene expression.

The antihyperlipidemic effects of BBR have also been confirmed in humans by some small clinical trials. One study evaluated the effects of 500 mg BBR twice a day in a hyperlipidemic group of 32 Asian patients without any other drug use for three months and compared the results with 11 patients using a placebo. The BBR significantly reduced the total cholesterol by 29%, triglycerides by 35%, and LDL-C by 25%. These results have been then confirmed in a larger trial carried out on 116 hyperlipidemic type 2 diabetic patients randomized to treatment with berberine 0.5 g thrice daily or a placebo. Beyond a similar decrease in plasma lipids, the berberine-treated patients also experienced a significant decrease in glycohemoglobin, and in both fasting and two-hour postprandial glucose levels compared with the placebo group.

A randomized controlled study provides evidence that the addition to diet and lifestyle changes of a patented combination of natural nutraceuticals, based on red yeast rice extract and berberine, can significantly improve the lipid profile versus diet alone in dyslipidemic subjects in whom a hypolipidemic therapy is not yet indicated or not well tolerated or contraindicated.

**Effects of berberine on insulin resistance**

Beyond a direct effect of berberine on lipid metabolism, recent preclinical and clinical evidence suggest that it increases insulin receptor expression and improves glucose utility. It has been observed that berberine acts as an insulin-sensitizing agent, therefore its activity has been compared with metformin in different animal models. In a rat model of type 2 diabetes, berberine showed better fasting plasma glucose and LDL-C lowering and better homeostasis model assessment of insulin resistance (HOMA-IR) than metformin by a mechanism involving retinol binding protein-4 (RBP-4) and glucose transporter-4 (GLUT-4). However, in another study, berberine was not inferior to metformin as an insulin-sensitizer.

Beyond the large preclinical literature, data on human glucose metabolism are really preliminary.
However, a study carried out on subjects affected by type 2 diabetes, showed that 500 mg of berberine three times a day was associated with a significant reduction in hemoglobin-a1 (HbA1) (−2%), fasting plasma glucose (−44%), postprandial glucose (−45%), fasting plasma insulin (−28%), and HOMA-IR index (−44%). In this study, berberine also significantly reduced the plasma total and LDL-C levels. Another study showed a nutraceutical containing berberine and chlorogenic acid was able to increase insulin-sensitivity and liver parameters for the short-term in overweight patients with mixed hyperlipidemia.

Berberine anti-arrhythmia effects

Recent studies indicate that BBR may significantly prolong the duration of the action potential and the effective refractoriness of the cardiac cells and may improve cardiac reentry rhythm by modifying the unidirectional conduction block to a bidirectional conduction block or delaying the duration of the reentrant pathway. It has been demonstrated that berberine may protect the cardiac cellular membrane from interference by hydroxyl radicals and intracellular calcium overload. By its action, BBR may abolish the delay after depolarization induced by intracellular calcium overload and may thereby terminate arrhythmias associated with triggered activation. In addition, one study has found that the effects of berberine on I(K1)/Kir2.1 may be an important mechanism for producing anti-arrhythmic effects. In the 24–48 h ambulatory monitoring of 100 patients with ventricular tachyarrhythmia, berberine caused a 50% or greater reduction in ventricular premature contractions in 62% of patients and a 90% or more reduction in 38% of patients.

Berberine anti-platelet aggregation effects

Some studies show that BBR has a significant anti-platelet effect, explained by inhibition of arachidonic acid metabolism and calcium influx, but also by a partial agonistic effect on platelet adrenoreceptors. BBR inhibited thromboxane synthesis induced by collagen, adenosine diphosphate and arachidonic acid, and it might inhibit arachidonic acid metabolism in platelets and endothelial cells. BBR can cause potassium channel blockade resulting in prolongation of the action potential in cat ventricular monocytes. On the other hand, recent evidence suggests that BBR can also have prothrombotic effect-enhancing tissue factor activity.

Conclusion

BBR is usually thought of as a traditional Chinese medicine, and recent discoveries have provided novel evidence that it may be considered a promising tool to counteract cardiovascular disorders. We believe that after further research, BBR will show a more important role in the treatment of cardiovascular disease.

References

1. Yang J, Lin J. Advance on study in anti-tumor mechanism of Berberine. China J Chin Mater Med. 2007;32:881–883, 934.
2. Birdsall TC, Kelly GS. Berberine: therapeutic potential of an alkaloid found in several medicinal plants. Altern Med Rev. 1997;2:94–103.
3. Pan GY, Wang GJ, Liu XD, Fawcett JP, Xie YY. The involvement of p-glycoprotein in berberine absorption. Pharmacol Toxicol. 2002;91:193–197.
4. Tsai PL, Tsai TH. Hepatobiliary excretion of berberine. Drug Metab Dispos. 2003;31:405–412.
5. Zuo F, Nakamura N, Akao T, Hattori M. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos. 2006;34:2064–2072.
6. Chen CM, Chang HC. Determination of berberine in plasma, urine and bile by high performance liquid chromatography. J Chromatogr. 1995;665:117–123.
7. Cicero AFG, Ertiek S. Berberine: metabolic and cardiovascular effects in preclinical and clinical trials. Nutr Diet Suppl. 2009;1:1–10.
8. Imanshahidi M, Hosseinzadeh H. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res. 2002;8:999–1012.
9. Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate. 1993;63:201–208.
10. Tan YZ, Wu AC, Tan BY, et al. Study on the interactions of berberine displace other drug from their plasma proteins binding sites. Chin Pharmaco Bull. 2002;18:576–578.
11. Guang Z, Xian HD, Sheng XY. The observation of experiment and clinic in therapy for heart failure with Berberine. Chin J Intern Med. 1991;30:581–582.
12. Zhang W, Chen SG, Ju HS, et al. Mechanisms of protective effects of berberine on ischemia/reperfusion injury in isolated rat heart. Methods Find Exp Clin Pharmacol. 1992;14:677–684.
13. Li BX, Yang BF, Zhou J, Xu CQ, Li YR. Inhibitory effects of berberine on IK1. IK and HERG channels of cardiac myocytes. Acta Pharmacol Sin. 2001;22:125–131.
14. Wang YX, Zheng YM. Ionic mechanism responsible for prolongation of cardiac action-potential duration by berberine. J Cardiovasc Pharmacol. 1997;30:214–222.
15. Wang YX, Yao XJ, Tan YH. Effects of berberine on delayed after depolarisations in ventricular muscles in vitro and in vivo. J Cardiovasc Pharmacol. 1994;23:716–722.
16. Hong Y, Hui SS, Chan BT, Hou J. Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy. Life Sci. 2003;72:2499–2507.
17. Hong Y, Hui SC, Chan TY, Hou JY. Effect of berberine on regression of pressure overload induced cardiac hypertrophy in rats. Am J Chin Med. 2002;30:589–599.
18. Huang WM, Yan H, Lin JM, Yu C, Zhang H. Beneficial effects of berberine on hemodynamics during acute ischemic left ventricular failure in dogs. Chin Med J. 1992;105:1014–1019.

19. Ko WH, Yao XQ, Lau CW, et al. Vasorelaxant and anti-proliferative effects of berberine. Eur J Pharmacol. 2000;399:187–196.

20. Marin-Neto JA, Maciel BC, Secches AL, Gallo Junior L. Cardiovascular effects of berberine in patients with severe congestive heart failure. Clin Cardiol. 1988;11:253–260.

21. Zeng XH, LI YY. Clinical observations of the effect of berberine for congestive heart failure. US Chin J Angiocardiomyopathy. 2001;6:308–311.

22. Caliceti C, Rizzo P, Cicero AF. Potential benefits of berberine in the management of perimenopausal syndrome. Oxid Med Cell Longev. 2015:2015;723093—723101.

23. Sola R, Valls RM, Puzo J, et al. Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial. PLoS One. 2014 Aug 1;9:e101978—e101987.

24. Lu H, Cassis LA, Daugherty A. Atherosclerosis and arterial blood pressure in mice. Curr Drug Targets. 2007;8:1181–1189.

25. Zhang LS. Clinical usage of berberine. Chin Rem Clin. 2004;41:78.

26. Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal regulated kinase-dependent stabilization of hepatic low density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol. 2005;25:2170–2176.

27. Lee S, Lim HJ, Park JH, Lee KS, Jang Y, Park HY. Berberine induced LDLR up-regulation involves JNK pathway. Biochem Biophys Res Commun. 2007;362:853–857.

28. Choi BH, Ahn IS, Kim YH, et al. Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3L1 Adipocyte. Exp Mol Med. 2006;38:599–605.

29. Brusq JM, Ancellin N, Grondin P, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res. 2006;47:1281–1288.

30. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344–1351.

31. Zhang Y, LI X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93:2559–2565.

32. Chang XX, Yan HM, Xu Q, et al. The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long term high-fat diet. Lipids Health Dis. 2012;11:86–93.

33. Trimarco B, Benvenuti C, Rosza F, Cimmino CS, Giudice R, Crispo S. Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet. Med J Nutr Metab. 2011;4:13–19.

34. Derosa G, Limas CP, Macías PC, Estrella A, Maffioli P. Dietary and nutraceutical approach to type 2 diabetes. Arch Med Sci. 2014;10:336–344.

35. Ko BS, Choi SB, Park SK, Jang JS, Kim YE, Park S. Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma. Biol Pharm Bull. 2005;28:1431–1437.

36. Zhang W, Xu YC, Guo FL, Meng Y, Li ML. Antidiabetic effects of cinnamaldehyde and berberine and their impacts on retinol binding protein 4 expression in rats with type 2 diabetes mellitus. Chin Med J. 2008;121:2124–2128.

37. Yin J, Hu R, Chen M, et al. Effects of berberine on glucose metabolism in vitro. Metabolism. 2002;51:1439–1443.

38. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57:712–717.

39. Cicero AF, Rosticci M, Parini A, et al. Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial. Nutr J. 2015;14.

40. Ming HW, Zhong XS, Qiou XY. The mechanical study of anti-arrhythmias—the observation to changes of delaying-activating fluxes of potassium ions with voltage clamp. Chin J Cardiol. 1992;5:310–311.

41. Chen SX. The blocking effect on channels of calcium ions by berberine in the rat Aorta. J Nanjing Univ TCM. 1996;12:20–22.

42. Wang LH, Yu CH, Fu Y, Li Q, Sun YQ. Berberine elicits anti-arrhythmic effects via IK1/Kir2.1 in the rat type 2 diabetic myocardial infarction model. Phytother Res. 2011;25:33–37.

43. Lau CW, Yao XQ, Chen ZY, Ko WH, Huang Y. Cardiovascular actions of berberine. Cardiovasc Drug Rev. 2001;19:234–244.

44. Huang HL, Zhu ZL, Wei SJ, Jiang H, Jiao BH. Effects of berberine on arachidonic acid metabolism in rabbit platelets and endothelial cells. Thromb Res. 2002;106:223–227.

45. Huang CG, Zhu ZL, Yang ZM. The progress in pharmacological researches on Berberine. Comun Inform Pharm. 1991;9:10–12.

46. Huang KC. The Pharmacology of Chinese Herbs. 2nd ed. New York: CRC Press; 1999.

47. Holy EW, Akhmedov A, Luscher TF, Tanner FC. Berberine a natural lipid-lowering drug, exerts prothrombic effects on vascular cells. J Mol Cell Cardiol. 2009;46:234–240.

Edited by Wei-Zhu Liu